电邮这篇文章 How to raise efficacy of gastroesophageal reflux disease treatment
- 作者: Vakhpushev Y.M.1, Potapova LO1, Mupavtseva OV1, Vakhrushev Y.M1, Potapova LO1, Muravtseva OV1
-
隶属关系:
- 期: 卷 81, 编号 2 (2009)
- 页面: 27-29
- 栏目: Editorial
- ##submission.dateSubmitted##: 09.04.2020
- ##submission.datePublished##: 15.02.2009
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30271
- ID: 30271
如何引用文章
全文:
详细
Aim. To specify dysfunction of the stomach and duodenum in gastroesophageal reflux disease (GRD) to offer more effective pathogenetic pharmacotherapy of GRD.
Material and methods. Fibroesophagogastroduodenoscopy with further assessment of esophageal mucosa condition by Savary-Miller, intragastric pH-metry, dynamic gastroscintigraphy and electrogastrography were made in 150 GRD patients.
Results. GRD patients were found to have significant disturbances of a motor-evacuatory function of the gastroduodenal complex. Addition of domperidon and mebeverin to routine combined treatment of GRD raises clinical efficacy of GRD treatment and promotes recovery of gastric and duodenal function though therapeutic efficacy of the above drugs depended on concomitant pathology.
Conclusion. Domperidon and mebeverin addition to combined treatment of GRD makes this treatment more effective.
Material and methods. Fibroesophagogastroduodenoscopy with further assessment of esophageal mucosa condition by Savary-Miller, intragastric pH-metry, dynamic gastroscintigraphy and electrogastrography were made in 150 GRD patients.
Results. GRD patients were found to have significant disturbances of a motor-evacuatory function of the gastroduodenal complex. Addition of domperidon and mebeverin to routine combined treatment of GRD raises clinical efficacy of GRD treatment and promotes recovery of gastric and duodenal function though therapeutic efficacy of the above drugs depended on concomitant pathology.
Conclusion. Domperidon and mebeverin addition to combined treatment of GRD makes this treatment more effective.
参考
- Ficher R. S., Ogorek C. P. Management of gastroesophageal reflux disease. Part one: Pathogenesis, symptoms and diagnosis. Pract. Gastroenterol. 1994; 6: 487-491.
- Hetzel D. Acid pump inhibitors. The treatment of gastroesophageal reflux. Aust. Fam. Physician 1998; 6: 487-491.
- Katzka P. A. Digestive system disorders. Gastroesophageal reflux disease. West. J. Med. 2000; 173: 48-53.
- Siegl A., Mayr J., Huber J., Urey E. Postprandial tahygastria is frequent in infants with gastroesophageal reflux. Pediatr. Surg. Int. 1998; 13: 560-571.
- Kahrilas P. J., Shi G., Manka M. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000; 118: 688-695.
- Пасечников В. Д. и др. Желудочные дизритмии как фактор риска развития гастроэзофагеальной рефлюксной болезни. Гастроэнтерол. Санкт.-Петербурга 2004; 2-3: 134.
- Циммерман Я. С., Телянер И. И. Синдром хронической дуоденальной непроходимости. Клин. мед. 2000; 6: 4-10.
- Вахрушев Я. М., Потапова Л. О. Способствующие факторы и некоторые патогенетические механизмы при гастроэзофагеальной болезни. Сиб. журн. гастроэнтерол. и гепатол. 2004; 18: 32-34.
补充文件
